×
About 4,295 results

ALLMedicine™ Advanced Prostate Cancer Center

Research & Reviews  1,361 results

Activation of the ABCB1-amplicon promotes cellular viability and resistance to docetaxe...
https://doi.org/10.1158/1535-7163.MCT-20-0983
Molecular Cancer Therapeutics; Lombard AP, Lou W et. al.

Jul 31st, 2021 - Docetaxel and cabazitaxel based taxane chemotherapy are critical components in the management of advanced prostate cancer. However, their efficacy is hindered due to de novo presentation with or the development of resistance. Characterizing models...

Prostate Cancer with Bone Metastases: Addressing Chronic Pain from the Perspective of t...
https://doi.org/10.1016/j.soncn.2021.151175
Seminars in Oncology Nursing; Pituskin E, Fairchild A

Jul 27th, 2021 - To discuss the symptom burden experienced among patients with castrate-resistant prostate cancer and bone metastases and the role of the oncology nurse practitioner in evaluation for palliative radiotherapy. These include PubMed, international con...

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor...
https://doi.org/10.1038/s41388-021-01914-2 10.1056/NEJMoa1815671 10.1056/NEJMoa1715546 10.1056/NEJMoa1014618 10.1056/NEJMoa1207506 10.1158/0008-5472.CAN-08-3795 10.1158/0008-5472.CAN-08-2764 10.1158/0008-5472.CAN-11-3892 10.1056/NEJMoa1315815 10.1074/jbc.M112.352930 10.1158/0008-5472.CAN-08-0594 10.1038/s43018-019-0001-2 10.1126/science.1141448 10.1038/cr.2011.75 10.1016/j.ccr.2010.04.027 10.1074/jbc.M114.553818 10.1158/0008-5472.CAN-12-4520 10.1038/onc.2008.320 10.1038/s42003-018-0105-8 10.18632/oncotarget.8493 10.1158/1078-0432.CCR-13-3296 10.1002/pros.21382 10.1073/pnas.1012443107 10.1186/s13059-015-0864-1 10.1038/s41467-018-07178-x 10.1371/journal.pone.0159675 10.1002/pros.23313 10.1016/j.eururo.2017.04.005 10.1073/pnas.1521738113 10.1016/j.neo.2019.12.003 10.1016/j.ejmech.2018.08.059 10.18632/oncotarget.4578 10.1016/j.cellsig.2017.04.001 10.1038/nrurol.2014.320 10.1038/onc.2012.144 10.1038/nchembio.546 10.1038/s41591-019-0668-z 10.1038/nchembio.2329 10.1126/science.aao5902 10.1016/j.celrep.2018.03.047 10.1038/nrd1159 10.3892/mco.2016.963 10.1007/978-1-61779-295-3_16 10.1093/jnci/92.19.1564 10.1158/0008-5472.CAN-07-6248 10.3816/CGC.2004.n.013 10.1158/0008-5472.CAN-17-3728 10.1158/0008-5472.CAN-14-3080 10.5455/jice.20140123040224 10.1073/pnas.0506580102
Oncogene Liu C, Armstrong CM et. al.

Jul 18th, 2021 - Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CR...

PARP inhibitors in advanced prostate cancer: when to use them?
https://doi.org/10.1530/ERC-21-0133
Endocrine-related Cancer; Díaz-Mejía N, García-Illescas D et. al.

Jul 14th, 2021 - Poly (ADP-ribose) polymerase (PARP) inhibitors have antitumor activity in advanced prostate cancer associated with loss of homologous recombination repair (HRR) function. About 20% of all patients with advanced prostate cancer present germline or ...

Cardiovascular Toxicity of Androgen Deprivation Therapy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254069
Current Cardiology Reports; Boland J, Choi W et. al.

Jul 4th, 2021 - Androgen deprivation therapy (ADT) is the standard of care for the treatment of advanced prostate cancer (PC). ADT, particularly with GnRH agonists, leads to increased risk of cardiovascular disease, including myocardial infarction, hypertension, ...

see more →

Guidelines  7 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  117 results

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
https://clinicaltrials.gov/ct2/show/NCT02531516

Mar 6th, 2020 - This is a randomized, double-blind, placebo-controlled, multicenter study of apalutamide plus GnRH agonist compared with GnRH agonist among participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation ther...

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
https://clinicaltrials.gov/ct2/show/NCT02406521

Mar 4th, 2020 - The FDA (the U.S. Food and Drug Administration) has not approved the combination of sorafenib and radium-223 or the combination of pazopanib and radium-223 as a treatment for any disease. Sorafenib and pazopanib are both approved as single agents ...

Phase I Trial of 225Ac−J591 in Patients With mCRPC
https://clinicaltrials.gov/ct2/show/NCT03276572

Mar 3rd, 2020 - This clinical trial is for men with advanced prostate cancer. The purpose of this study is to find the highest dose level of the study drug, 225Ac-J591 that can be given without severe side effects. The research study is being done because the sta...

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
https://clinicaltrials.gov/ct2/show/NCT02552394

Feb 28th, 2020 - J591 is a de-immunized monoclonal antibody against the extracellular domain of prostate-specific membrane antigen (PSMA). Background data demonstrate that mAb Hu-J591 doses as low as 20 mg may lead to a decrease in CTCs and that doses up to 300 mg...

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT00430183

Jan 13th, 2020 - This randomized trial tests whether the addition of chemohormonal therapy improves PSA-progression free survival in patients with high risk, clinically-localized prostate cancer. The neoadjuvant approach is taken since there appears to be a higher...

see more →

News  223 results

Common Advanced Prostate Cancer Treatments Not Tied to Significant Cognitive Decline
https://www.medscape.com/viewarticle/955117

Jul 21st, 2021 - (Reuters Health) - Several therapies commonly used to treat men with metastatic castration-resistant prostate cancer don't appear to cause a significant decline in cognitive function, a small study suggests. Researchers examined data on 155 men 65...

Institute of Cancer Research Criticises NICE Rejection of Abiraterone
https://www.medscape.com/viewarticle/954899

Jul 16th, 2021 - The Institute of Cancer Research (ICR) has expressed disappointment at the decision by The National Institute for Health and Care Excellence (NICE) not to approve abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer....

NICE Publishes Draft Guidance Recommending Enzalutamide for Prostate Cancer
https://www.medscape.com/viewarticle/952659

Jun 8th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance on the use of the androgen receptor inhibitor enzalutamide (Xtandi, Astellas), plus androgen deprivation therapy (ADT), as an option for treating prostate ca...

Study Shows UK Sniffer Dogs Have a Nose for Prostate Cancer
https://www.medscape.com/viewarticle/946111

Feb 19th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in  PLoS One,  tested the clinical fea...

Relugolix Confirmed to Cut Menstrual Bleed by Half in Most Women With Fibroids
https://www.medscape.com/viewarticle/945995

Feb 18th, 2021 - (Reuters Health) - Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medici...

see more →

Patient Education  1 results see all →